Navigation Links
Scripps Research scientists shed new light on how antibodies fight HIV
Date:9/6/2007

By furthering scientists understanding of the molecular mechanisms that separate the minority of successful HIV antibodies from the majority of ineffective antibodies, the work may have implications for future attempts to design an HIV vaccine.

The study was published on September 6, 2007, in the journal Nature.

This study is part of the effort to understand how protection against HIV occurs, says Dennis Burton, a professor at The Scripps Research Institute. If we really understand this, then we can design tailor-made vaccines in a way that has never been done before.

Although vaccines have long been used with great success to prevent diseases, scientists are still learning about the exact mechanisms of how vaccines work and how the antibodies that vaccines prompt the body to create can neutralize a pathogen. The spread of HIV, which is resistant to most antibodies the body produces against it, has made fully understanding this method of action more urgent.

With this in mind, Burton and colleagues sought to tease apart the action of the b12 antibody-one of the rare antibodies that protects against the HIV virus. The antibody, first identified by Burton, Scripps Research Professor Carlos Barbas III, and colleagues in 1992, originally came from the bone marrow of a 31-year-old male who had been HIV positive without symptoms for six years.

In the current study, researchers created mutated versions of b12 to see what effect various changes would have on the antibodys effectiveness.

Hopefully, we can work backwards towards a vaccine, using b12 and the very few other really great, broadly neutralizing antibodies against HIV that have been found, says Scripps Research Senior Research Associate Ann Hessell, who was first author of the Nature paper jointly with Lars Hangartner, a Scripps Research postdoctoral fellow.

Results from the new study suggest the importance of antibody activity against both infected cells and free virus for effective protection. As well as simply binding to HIV, protection was dependent upon the ability of antibodies to interact with immune cell Fc receptors.

Fc receptors are found on the surface of immune cells, such as natural killer cells. The Fc receptor binds to the Fc region of an antibody after an antibody binds to a pathogen, targeting the pathogen for attack by the immune system. Although Fc receptor function was known to be important for the function of antibodies against other diseases, a role in protecting against HIV had never before been demonstrated.

Burtons team examined the ability of two antibodies mutated from b12, dubbed KA and LALA, to prevent infection using the SHIV/macaque model, in which macaques are challenged with a hybrid human-simian virus that infects the model but is recognized by human antibodies. The KA antibody contained a mutation that prevented it from interacting with the complement cascade, a major component of the immune system responsible for destroying invading pathogens. The LALA antibody contained a mutation that rendered it unable to interact with either the complement pathway or the Fc receptor.

In both mutants, the site where the antibody binds to free-floating virus was unaltered, allowing the researchers specifically to investigate the importance of the complement cascade and Fc receptor system for preventing infection.

We saw that the KA antibody, which could still bind to the Fc receptors on the immune cells but not to the complement cascade, protected the animals from becoming infected just as the wild type b12 antibody, says Hessell. In contrast, the LALA group became infected much like the controls.

The results provide the first evidence that the Fc receptor, but not the complement cascade, is important to the function of the b12 antibody in preventing HIV infection.

Additional in vitro experiments revealed that the wild type and KA antibodies, but not the LALA antibody, blocked infection more efficiently in the presence of other effector cells of the immune system.

Our results are fully consistent with the antibody doing two jobs, says Burton, job one, stick to the virus; job two, recruit immune cells to come and kill infected cells.


'/>"/>

Contact: Keith McKeown
kmckeown@scripps.edu
858-784-8134
Scripps Research Institute
Source:Eurekalert

Related medicine news :

1. Kidney Stones - Interesting New Research implicates bacteria as its cause
2. Stem cell research- now Nobel Laureates join the debate
3. Researchers urge caution in using ear tube surgery
4. Paracetamol May Cause Live Damage Warns Consumer Education and Research Centre
5. Spouses and other partners lower blood pressure says new research
6. Researchers Scale to assess the Severity of Epilepsy in Kids
7. Ecstasy shrinks brain!!-researchers unveil the secrets of MDMA.
8. Research of Ritalin
9. New Hair in 15 Days Could Now Be A Possibility Say Researchers
10. Researchers at Cornell University as been reported using research fund by false claims
11. Better Research Rats To Help In Learning About Hypertension
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/22/2017)... ... , ... The San Juan Capistrano summer camp team at the Boys and Girls ... summer camps to provide physical activities for all campers. To read the report, click ... With an increase in specialty camps that focus on what the report terms as “sitting ...
(Date:4/21/2017)... ... ... Chicago plastic surgeon, Dr. Anil R. Shah, MD , has found the ... located on the forehead usually attributed to a facial fracture. Their appearance is not ... has discovered an approach that is minimally invasive. He is an expert at this ...
(Date:4/21/2017)... City, Colo. (PRWEB) , ... April 21, 2017 , ... ... of the Flex House, the next project in the company’s esteemed VISION House demonstration ... help homeowners use exactly the amount of resources they need to live affordably and ...
(Date:4/21/2017)... VA (PRWEB) , ... April 21, 2017 , ... ... its first weeklong campaign, AWARE: A Week of Addiction and Recovery Education, from ... evidence in treating and preventing substance use disorders. , The mission of ...
(Date:4/21/2017)... Annapolis, MD (PRWEB) , ... ... ... leading accreditation organization promoting quality-based imaging practices, is seeking candidates to serve ... activities for diagnostic imaging. , “RadSite’s ultimate mission is improving image ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017  CVS Pharmacy, ... today unveiled a new store design to enhance ... of healthier food, health-focused products and expanded beauty ... to help customers discover new offerings. Together with ... next evolution of the customer experience at CVS ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... , April 19, 2017  IRIDEX Corporation (Nasdaq: ... release financial results for the first quarter 2017 after ... The Company,s management team will host a corresponding conference ... ET. Investors interested in listening to the ... for domestic callers or (703) 326-3030 for international callers, ...
Breaking Medicine Technology: